Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cardiovascular Diabetology
Published in: Cardiovascular Diabetology 1/2012

Open Access 01-12-2012 | Original investigation

Uncoupling protein 2 gene polymorphisms are associated with obesity

Authors: Sukma Oktavianthi, Hidayat Trimarsanto, Clarissa A Febinia, Ketut Suastika, Made R Saraswati, Pande Dwipayana, Wibowo Arindrarto, Herawati Sudoyo, Safarina G Malik

Published in: Cardiovascular Diabetology | Issue 1/2012

Login to get access

Abstract

Background

Uncoupling protein 2 (UCP2) gene polymorphisms have been reported as genetic risk factors for obesity and type 2 diabetes mellitus (T2DM). We examined the association of commonly observed UCP2 G(−866)A (rs659366) and Ala55Val (C > T) (rs660339) single nucleotide polymorphisms (SNPs) with obesity, high fasting plasma glucose, and serum lipids in a Balinese population.

Methods

A total of 603 participants (278 urban and 325 rural subjects) were recruited from Bali Island, Indonesia. Fasting plasma glucose (FPG), triglyceride (TG), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) were measured. Obesity was determined based on WHO classifications for adult Asians. Participants were genotyped for G(−866)A and Ala55Val polymorphisms of the UCP2 gene.

Results

Obesity prevalence was higher in urban subjects (51%) as compared to rural subjects (23%). The genotype, minor allele (MAF), and heterozygosity frequencies were similar between urban and rural subjects for both SNPs. All genotype frequencies were in Hardy-Weinberg equilibrium. A combined analysis of genotypes and environment revealed that the urban subjects carrying the A/A genotype of the G(−866)A SNP have higher BMI than the rural subjects with the same genotype. Since the two SNPs showed strong linkage disequilibrium (D’ = 0.946, r2 = 0.657), a haplotype analysis was performed. We found that the AT haplotype was associated with high BMI only when the urban environment was taken into account.

Conclusions

We have demonstrated the importance of environmental settings in studying the influence of the common UCP2 gene polymorphisms in the development of obesity in a Balinese population.
Literature
1.
2.
Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of diabetes for 2010 and 2030. Res Clin Pract. 2010, 87: 4-14. 10.1016/j.diabres.2009.10.007.CrossRef
3.
Hossain P, Kawar B, El Nahas M: Obesity and diabetes in the developing world – a growing challenge. N Engl J Med. 2007, 356: 213-215. 10.1056/NEJMp068177.CrossRefPubMed
4.
Misra A, Khurana L: Obesity and the metabolic syndrome in developing countries. J Clin Endocrinol Metab. 2008, 93: S9-S30. 10.1210/jc.2008-1595.CrossRefPubMed
5.
McCarthy MI: Genomics, type 2 diabetes, and obesity. N Engl J Med. 2010, 363: 2339-2350. 10.1056/NEJMra0906948.CrossRefPubMed
6.
Wang CP, Chung FM, Shin SJ, Lee YJ: Congenital and environmental factors associated with adipocyte dysregulation as defects of insulin resistance. Rev Diabet Stud. 2007, 4: 77-84. 10.1900/RDS.2007.4.77.PubMedCentralCrossRefPubMed
7.
Fleury C, Neverova M, Collins S, Raimbault S, Champigny O, Levi-Meyrueis C, Bouillaud F, Seldin MF, Surwit RS, Ricquier D, Warden CH: Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia. Nat Genet. 1997, 15: 269-272.CrossRefPubMed
8.
Chan CB, Kashemsant N: Regulation of insulin secretion by uncoupling protein. Biochem Soc Trans. 2006, 34: 802-805. 10.1042/BST0340802.CrossRefPubMed
9.
Zhang CY, Baffy G, Perret P, Krauss S, Peroni O, Grujic D, Hagen T, Vidal-Puig AJ, Boss O, Kim YB, Zheng XX, Wheeler MB, Shulman GI, Chan CB, Lowell BB: Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes. Cell. 2001, 105: 745-755. 10.1016/S0092-8674(01)00378-6.CrossRefPubMed
10.
Chan CB, MacDonald PE, Saleh MC, Johns DC, Marbàn E, Wheeler MB: Overexpression of uncoupling protein 2 inhibits glucose-stimulated insulin secretion from rat islets. Diabetes. 1999, 48: 1482-1486. 10.2337/diabetes.48.7.1482.CrossRefPubMed
11.
Chan CB, De Leo D, Joseph JW, McQuaid TS, Ha XF, Xu F, Tsushima RG, Pennefather PS, Salapatek AM, Wheeler MB: Increased uncoupling protein-2 levels in beta-cells are associated with impaired glucose-stimulated insulin secretion: mechanism of action. Diabetes. 2001, 50: 1302-1310. 10.2337/diabetes.50.6.1302.CrossRefPubMed
12.
Armstrong MB, Towle HC: Polyunsaturated fatty acids stimulate hepatic UCP-2 expression via a PPARalpha-mediated pathway. Am J Physiol Endocrinol Metab. 2001, 281: E1197-E1204.PubMed
13.
Andrews ZB, Erion DM, Beiler R, Choi CS, Shulman GI, Horvath TL: Uncoupling protein-2 decreases the lipogenic actions of ghrelin. Endocrinology. 2010, 151: 2078-2086. 10.1210/en.2009-0850.PubMedCentralCrossRefPubMed
14.
Sheets AR, Fülöp P, Derdák Z, Kassai A, Sabo E, Mark NM, Paragh G, Wands JR, Baffy G: Uncoupling protein-2 modulates the lipid metabolic response to fasting in mice. Am J Physiol Gastrointest Liver Physiol. 2008, 294: G1017-G1024. 10.1152/ajpgi.00016.2008.PubMedCentralCrossRefPubMed
15.
Pecqueur C, Bui T, Gelly C, Hauchard J, Barbot C, Bouillaud F, Ricquier D, Miroux B, Thompson CB: Uncoupling protein-2 controls proliferation by promoting fatty acid oxidation and limiting glycolysis-derived pyruvate utilization. FASEB J. 2008, 22: 9-18.CrossRefPubMed
16.
Briaud I, Kelpe CL, Johnson LM, Tran PO, Poitout V: Differential effects of hyperlipidemia on insulin secretion in islets of langerhans from hyperglycemic versus normoglycemic rats. Diabetes. 2002, 51: 662-668. 10.2337/diabetes.51.3.662.CrossRefPubMed
17.
Joseph JW, Koshkin V, Zhang CY, Wang J, Lowell BB, Chan CB, Wheeler MB: Uncoupling protein 2 knockout mice have enhanced insulin secretory capacity after a high-fat diet. Diabetes. 2002, 51: 3211-3219. 10.2337/diabetes.51.11.3211.CrossRefPubMed
18.
Esterbauer H, Schneitler C, Oberkofler H, Ebenbichler C, Paulweber B, Sandhofer F, Ladurner G, Hell E, Strosberg AD, Patsch JR, Krempler F, Patsch W: A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans. Nat Genet. 2001, 28: 178-183. 10.1038/88911.CrossRefPubMed
19.
Krempler F, Esterbauer H, Weitgasser R, Ebenbichler C, Patsch JR, Miller K, Xie M, Linnemayr V, Oberkofler H, Patsch W: A functional polymorphism in the promoter of UCP2 enhances obesity risk but reduces type 2 diabetes risk in obese middle-aged humans. Diabetes. 2002, 51: 3331-3335. 10.2337/diabetes.51.11.3331.CrossRefPubMed
20.
Martinez-Hervas S, Mansego ML, de Marco G, Martinez F, Alonso MP, Morcillo S, Rojo-Martinez G, Real JT, Ascaso JF, Redon J, Martin Escudero JC, Soriguer F, Chaves FJ: Polymorphisms of the UCP2 gene are associated with body fat distribution and risk of abdominal obesity in Spanish population. Eur J Clin Invest. 2012, 42: 171-178. 10.1111/j.1365-2362.2011.02570.x.CrossRefPubMed
21.
Srivastava N, Prakash J, Lakhan R, Agarwal CG, Pant DC, Mittal B: A common polymorphism in the promoter of UCP2 is associated with obesity and hyperinsulenemia in northern Indians. Mol Cell Biochem. 2010, 337: 293-298. 10.1007/s11010-009-0311-2.CrossRefPubMed
22.
Dhamrait SS, Stephens JW, Cooper JA, Acharya J, Mani AR, Moore K, Miller GJ, Humphries SE, Hurel SJ, Montgomery HE: Cardiovascular risk in healthy men and markers of oxidative stress in diabetic men are associated with common variation in the gene for uncoupling protein 2. Eur Heart J. 2004, 25: 468-475. 10.1016/j.ehj.2004.01.007.CrossRefPubMed
23.
Humphries SE, Cooper JA, Talmud PJ, Miller GJ: Candidate gene genotypes, along with conventional risk factor assessment, improve estimation of coronary heart disease risk in healthy UK men. Clin Chem. 2007, 53: 8-16.CrossRefPubMed
24.
Cheurfa N, Dubois-Laforgue D, Ferrarezi DA, Reis AF, Brenner GM, Bouché C, Le Feuvre C, Fumeron F, Timsit J, Marre M, Velho G: The common -866 G > A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men. Diabetes. 2008, 57: 1063-1068. 10.2337/db07-1292.CrossRefPubMed
25.
Yang M, Huang Q, Wu J, Yin JY, Sun H, Liu HL, Zhou HH, Liu ZQ: Effects of UCP2–866 G/A and ADRB3 Trp64Arg on rosiglitazone response in Chinese patients with Type 2 diabetes. Br J Clin Pharmacol. 2009, 68: 14-22. 10.1111/j.1365-2125.2009.03431.x.PubMedCentralCrossRefPubMed
26.
Hamada T, Kotani K, Fujiwara S, Sano Y, Domichi M, Tsuzaki K, Takahashi K, Sakane N: The UCP2-866 A/A genotype is associated with low density lipoprotein particle sizes in the general population. Med Sci Monit. 2008, 14: CR107-CR111.PubMed
27.
Yu X, Jacobs DR, Schreiner PJ, Gross MD, Steffes MW, Fornage M: The uncoupling protein 2 Ala55Val polymorphism is associated with diabetes mellitus: the CARDIA study. Clin Chem. 2005, 51: 1451-1456. 10.1373/clinchem.2004.044859.CrossRefPubMed
28.
Saraswati MR, Suastika K, Malik SG, Sudoyo H: The uncoupling 2 Ala55Val polymorphism is associated with diabetes mellitus in a Balinese population. JAFES. 2011, 26: 39-43.CrossRef
29.
Wang TN, Huang MC, Lin HL, Hsiang CH, Ko AM, Chang WT, Ko YC: UCP2 A55V variant is associated with obesity and related phenotypes in an aboriginal community in Taiwan. Int J Obes. 2007, 31: 1746-1752. 10.1038/sj.ijo.0803648.CrossRef
30.
Astrup A, Toubro S, Dalgaard LT, Urhammer SA, Sorensen TI, Pedersen O: Impact of the v/v 55 polymorphism of the uncoupling protein 2 gene on 24-h energy expenditure and substrate oxidation. Int J Obes Relat Metab Disord. 1999, 23: 1030-1034. 10.1038/sj.ijo.0801040.CrossRefPubMed
31.
Buemann B, Schierning B, Toubro S, Bibby BM, Sørensen T, Dalgaard L, Pedersen O, Astrup A: The association between the val/ala-55 polymorphism of the uncoupling protein 2 gene and exercise efficiency. Int J Obes Relat Metab Disord. 2001, 25: 467-471. 10.1038/sj.ijo.0801564.CrossRefPubMed
32.
Malik SG, Saraswati MR, Suastika K, Trimarsanto H, Oktavianthi S, Sudoyo H: Association of beta3-adrenergic receptor (ADRB3) Trp64Arg gene polymorphism with obesity and metabolic syndrome in the Balinese: a pilot study. BMC Res Notes. 2011, 4: 167-10.1186/1756-0500-4-167.PubMedCentralCrossRefPubMed
33.
Suastika K, Dwipayana P, Saraswati MR, Kuswardhani T, Astika N, Putrawan IB, Matsumoto K, Kajiwara N, Taniguchi H: Relationship between age and metabolic disorders in the population of Bali. J Clin Geron Ger. 2011, 2: 47-52. 10.1016/j.jcgg.2011.03.001.CrossRef
34.
WHO Regional Office for the Western Pacific:The Asia-Pacific perspective: redefining obesity and its treatment. 2000, World Health Organization, Manila, Philippines.
35.
Pan WH, Yeh WT: How to define obesity? Evidence-based multiple action points for public awareness, screening, and treatment: an extension of Asian-Pacific recommendations. Asia Pac J Clin Nutr. 2008, 17: 370-374.PubMed
36.
World Health Organization:Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia: Report of a WHO consultation. 2006, World Health Organization, Geneva.
37.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001, 285: 2486-2497. 10.1001/jama.285.19.2486.CrossRef
38.
Bereczky S, Martensson A, Gil JP, Farnert A: Short report: rapid DNA extraction from archive blood spots on filter paper for genotyping ofPlasmodium falciparum. Am J Trop Med Hyg. 2005, 72: 249-251.PubMed
39.
Miller SA, Dykes DD, Polesky HF: A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res. 1988, 16: 1215-10.1093/nar/16.3.1215.PubMedCentralCrossRefPubMed
40.
Sesti G, Cardellini M, Marini MA, Frontoni S, D'Adamo M, Del Guerra S, Lauro D, De Nicolais P, Sbraccia P, Del Prato S, Gambardella S, Federici M, Marchetti P, Lauro R: A common polymorphism in the promoter of UCP2 contributes to the variation in insulin secretion in glucose-tolerant subjects. Diabetes. 2003, 52: 1280-1283. 10.2337/diabetes.52.5.1280.CrossRefPubMed
41.
Kubota T, Mori H, Tamori Y, Okazawa H, Fukuda T, Miki M, Ito C, Bouilaud F, Kasuga M: Molecular screening of uncoupling protein 2 gene in patients with noninsulin-dependent diabetes mellitus or obesity. J Clin Endocrinol Metab. 1998, 83: 2800-2804. 10.1210/jc.83.8.2800.PubMed
42.
Schaid DJ, Rowland CM, Tines DE, Jacobson RM, Poland GA: Score test for association between traits and haplotypes when linkage phase in ambiguous. Am J Hum Genet. 2002, 70: 425-434. 10.1086/338688.PubMedCentralCrossRefPubMed
43.
Schaid DJ, Olson JM, Gauderman WJ, Elston RC: Regression models for linkage: issues of traits, covariates, heterogeneity, and interaction. Hum Hered. 2003, 55: 86-96. 10.1159/000072313.CrossRefPubMed
44.
Lake SL, Lyon H, Tantisira K, Silverman EK, Weiss ST, Laird NM, Schaid DJ: Estimation and tests of haplotype-environtment interaction when linkage phase is ambiguous. Hum Hered. 2003, 55: 56-65. 10.1159/000071811.CrossRefPubMed
45.
Kring SI, Larsen LH, Holst C, Toubro S, Hansen T, Astrup A, Pedersen O, Sørensen TI: Genotype-phenotype associations in obesity dependent on definition of the obesity phenotype. Obes Facts. 2008, 1: 138-145. 10.1159/000137665.CrossRefPubMed
46.
Yoon Y, Park BL, Cha MH, Kim KS, Cheong HS, Cho YH, Shin HD: Effects of genetic polymorphisms of UCP2 and UCP3 on very low calorie diet-induced body fat reduction in Korean female subjects. Biochem Biophys Res Commun. 2007, 359: 451-456. 10.1016/j.bbrc.2007.05.110.CrossRefPubMed
47.
Le Fur S, Le Stunff C, Dos Santos C, Bougnères P: The common −866 G/A polymorphism in the promoter of uncoupling protein 2 is associated with increased carbohydrate and decreased lipid oxidation in juvenile obesity. Diabetes. 2004, 53: 235-239.CrossRefPubMed
48.
Kovacs P, Ma L, Hanson RL, Franks P, Stumvoll M, Bogardus C, Baier LJ: Genetic variation in UCP2 (uncoupling protein-2) is associated with energy metabolism in Pima Indians. Diabetologia. 2005, 48: 2292-2295. 10.1007/s00125-005-1934-9.CrossRefPubMed
49.
Hsiao TJ, Wu LSH, Hwang Y, Huang WY, Lin E: Effect of the common -866 G/A Polymorphism of the uncoupling protein 2 gene on weight loss and body composition under sibutramine therapy in an obese Taiwanese population. Mol Diagn Ther. 2010, 14: 101-106.CrossRefPubMed
50.
Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, Timsit J, Velho G: A polymorphism in the promoter of UCP2 gene modulates lipid levels in patients with type 2 diabetes. Mol Genet Metab. 2004, 82: 339-344. 10.1016/j.ymgme.2004.06.008.CrossRefPubMed
51.
Lapice E, Pinelli M, Pisu E, Monticelli A, Gambino R, Pagano G, Valsecchi S, Cocozza S, Riccardi G, Vaccaro O: Uncoupling protein 2 G(−866)A polymorphism: a new gene polymorphism associated with C-reactive protein in type 2 diabetic patients. Cardiovasc Diabetol. 2010, 9: 68-10.1186/1475-2840-9-68.PubMedCentralCrossRefPubMed
52.
Ling Y, Li X, Gu Q, Chen H, Lu D, Gao X: A common polymorphism rs3781637 in MTNR1B is associated with type 2 diabetes and lipids levels in Han Chinese individuals. Cardiovasc Diabetol. 2011, 10: 27-10.1186/1475-2840-10-27.PubMedCentralCrossRefPubMed
53.
Ko GT, Wai HP, Tang JS: Effects of age on plasma glucose levels in non-diabetic Hong Kong Chinese. Croat Med J. 2006, 47: 709-713.PubMedCentralPubMed
54.
Hong J, Stubbins RE, Smith RR, Harvey AE, Núñez NP: Differential susceptibility to obesity between male, female and ovariectomized female mice. Nutr J. 2009, 8: 11-10.1186/1475-2891-8-11.PubMedCentralCrossRefPubMed
Metadata
Title
Uncoupling protein 2 gene polymorphisms are associated with obesity
Authors
Sukma Oktavianthi
Hidayat Trimarsanto
Clarissa A Febinia
Ketut Suastika
Made R Saraswati
Pande Dwipayana
Wibowo Arindrarto
Herawati Sudoyo
Safarina G Malik
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Cardiovascular Diabetology / Issue 1/2012
Electronic ISSN: 1475-2840
DOI
https://doi.org/10.1186/1475-2840-11-41

Other articles of this Issue 1/2012

Cardiovascular Diabetology 1/2012 Go to the issue

Original investigation

Clinical significance of troponin elevations in acute decompensated diabetes without clinical acute coronary syndrome

Original investigation

Higher normal ranges of urine albumin-to-creatinine ratio are independently associated with carotid intima-media thickness

Original investigation

Association between 9p21 genetic variants and mortality risk in a prospective cohort of patients with type 2 diabetes (ZODIAC-15)

Original investigation

Reduced lung function is independently associated with increased risk of type 2 diabetes in Korean men

Study protocol

Detecting DNA synthesis of neointimal formation after catheter balloon injury in GK and in Wistar rats: using 5-ethynyl-2'-deoxyuridine

Review

Mammalian target of rapamycin signaling in diabetic cardiovascular disease
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits